AIMP2 and breast carcinoma: In addition, pan-cancer bioinformatic analyses have identified AIMP2 as an immune-associated molecule whose aberrant expression correlates with tumour immune infiltration and patient survival, suggesting its potential as a biomarker in breast cancer immunomodulation [124].